BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rosenstock J, Klaff LJ, Schwartz S, Northrup J, Holcombe JH, Wilhelm K, Trautmann M. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care. 2010;33:1173-1175. [PMID: 20332357 DOI: 10.2337/dc09-1203] [Cited by in Crossref: 148] [Cited by in F6Publishing: 161] [Article Influence: 12.3] [Reference Citation Analysis]
Number Citing Articles
1 Koldemir Gündüz M, Kaymak G, Kanbur E, Berikten D, Şahin MC, Şener H, Yerlikara A. Eksenatidin 3D 3T3-L1 Adipositleri Üzerindeki Ekspresyon Profilinin Mikrodizin Analizi ile Belirlenmesi. Iğdır Üniv Fen Bil Enst Der 2022. [DOI: 10.21597/jist.1143528] [Reference Citation Analysis]
2 Chiu M, Moist L, Al-Jaishi A, Jain AK. Recognition of Obesity and Perceptions of Weight Loss Management in Patients With Chronic Kidney Disease: A Retrospective Cross-Sectional Study. Can J Kidney Health Dis 2022;9:20543581221129465. [PMID: 36246343 DOI: 10.1177/20543581221129465] [Reference Citation Analysis]
3 Walker EG, Lo KR, Pahl MC, Shin HS, Lang C, Wohlers MW, Poppitt SD, Sutton KH, Ingram JR. An extract of hops (Humulus lupulus L.) modulates gut peptide hormone secretion and reduces energy intake in healthy-weight men: a randomized, crossover clinical trial. The American Journal of Clinical Nutrition 2022;115:925-940. [DOI: 10.1093/ajcn/nqab418] [Reference Citation Analysis]
4 Liu Y, Luo X. New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation. Front Med . [DOI: 10.1007/s11684-021-0873-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Velychko V, Mankovskyi B, Tatarchuk T, Lahoda D, Todurov I, Lishchyshyna O. A contemporary view on obesity treatment in adults. RE 2021. [DOI: 10.18370/2309-4117.2021.61.45-50] [Reference Citation Analysis]
6 Smith KR, Moran TH. Gastrointestinal peptides in eating-related disorders. Physiol Behav 2021;238:113456. [PMID: 33989649 DOI: 10.1016/j.physbeh.2021.113456] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
7 Walker EG, Lo KR, Pahl MC, Shin HS, Lang C, Wohlers MW, Poppitt SD, Sutton KH, Ingram JR. An extract of hops (Humulus lupulus L.) modulates gut peptide hormone secretion and reduces energy intake in healthy weight men: a randomised, cross-over clinical trial.. [DOI: 10.1101/2021.06.25.21259514] [Reference Citation Analysis]
8 Casey R, Adelfio A, Connolly M, Wall A, Holyer I, Khaldi N. Discovery through Machine Learning and Preclinical Validation of Novel Anti-Diabetic Peptides. Biomedicines 2021;9:276. [PMID: 33803471 DOI: 10.3390/biomedicines9030276] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
9 Myat A, Redwood SR, Arri S, Gersh BJ, Bhatt DL, Marber MS. Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS): a double-blind randomised placebo-controlled crossover trial. Diabetol Metab Syndr 2021;13:17. [PMID: 33579317 DOI: 10.1186/s13098-021-00635-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Roth CL, Perez FA, Whitlock KB, Elfers C, Yanovski JA, Shoemaker AH, Abuzzahab MJ. A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity. Diabetes Obes Metab 2021;23:363-73. [PMID: 33026160 DOI: 10.1111/dom.14224] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
11 Tao T, Zhang Y, Zhu YC, Fu JR, Wang YY, Cai J, Ma JY, Xu Y, Gao YN, Sun Y, Fan W, Liu W. Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study. J Clin Endocrinol Metab 2021;106:e1420-32. [PMID: 32995892 DOI: 10.1210/clinem/dgaa692] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
12 Clauss SB, de Ferranti SD. Update on Preventive Cardiology. Pediatr Clin North Am 2020;67:923-44. [PMID: 32888690 DOI: 10.1016/j.pcl.2020.06.006] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Fiorentino TV, Pedace E, Succurro E, Andreozzi F, Perticone M, Sciacqua A, Perticone F, Sesti G. Individuals With Prediabetes Display Different Age-Related Pathophysiological Characteristics. J Clin Endocrinol Metab 2019;104:2911-24. [PMID: 30848793 DOI: 10.1210/jc.2018-02610] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
14 Knowler WC, Crandall JP. Pharmacologic Randomized Clinical Trials in Prevention of Type 2 Diabetes. Curr Diab Rep 2019;19:154. [PMID: 31792721 DOI: 10.1007/s11892-019-1268-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Domecq JP, Prutsky G, Elraiyah T, Wang Z, Mauck KF, Brito JP, Undavalli C, Sundaresh V, Prokop LJ, Montori VM, Murad MH. Medications Affecting the Biochemical Conversion to Type 2 Diabetes: A Systematic Review and Meta-Analysis. The Journal of Clinical Endocrinology & Metabolism 2019;104:3986-95. [DOI: 10.1210/jc.2019-01269] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Mahat RK, Singh N, Arora M, Rathore V. Health risks and interventions in prediabetes: A review. Diabetes Metab Syndr 2019;13:2803-11. [PMID: 31405710 DOI: 10.1016/j.dsx.2019.07.041] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
17 Andersen A, Lund A, Knop FK, Vilsbøll T. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol 2018;14:390-403. [PMID: 29728598 DOI: 10.1038/s41574-018-0016-2] [Cited by in Crossref: 204] [Cited by in F6Publishing: 211] [Article Influence: 68.0] [Reference Citation Analysis]
18 Petersen J, Strømgaard K, Frølund B, Clemmensen C. Designing Poly-agonists for Treatment of Metabolic Diseases: Challenges and Opportunities. Drugs 2019;79:1187-97. [DOI: 10.1007/s40265-019-01153-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
19 Nolen-doerr E, Stockman M, Rizo I. Mechanism of Glucagon-Like Peptide 1 Improvements in Type 2 Diabetes Mellitus and Obesity. Curr Obes Rep 2019;8:284-91. [DOI: 10.1007/s13679-019-00350-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
20 Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY. Endocr Pract 2019;25:69-100. [PMID: 30742570 DOI: 10.4158/CS-2018-0535] [Cited by in Crossref: 199] [Cited by in F6Publishing: 219] [Article Influence: 66.3] [Reference Citation Analysis]
21 Jiang P, Ma C, Hao J, Han Y, Li M. Construction of a dietary-cure Saccharomyces cerevisiae expressing long-acting glucagon-like peptide-1 and investigation of its hypoglycemic activity in type 2 diabetes mellitus mouse model. J Biosci 2019;44:9. [DOI: 10.1007/s12038-018-9831-9] [Reference Citation Analysis]
22 Zhou J, Poudel A, Chandramani-Shivalingappa P, Xu B, Welchko R, Li L. Liraglutide induces beige fat development and promotes mitochondrial function in diet induced obesity mice partially through AMPK-SIRT-1-PGC1-α cell signaling pathway. Endocrine 2019;64:271-83. [PMID: 30535743 DOI: 10.1007/s12020-018-1826-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
23 Pilitsi E, Farr OM, Polyzos SA, Perakakis N, Nolen-Doerr E, Papathanasiou AE, Mantzoros CS. Pharmacotherapy of obesity: Available medications and drugs under investigation. Metabolism 2019;92:170-92. [PMID: 30391259 DOI: 10.1016/j.metabol.2018.10.010] [Cited by in Crossref: 110] [Cited by in F6Publishing: 119] [Article Influence: 27.5] [Reference Citation Analysis]
24 Siskind D, Hahn M, Correll CU, Fink-jensen A, Russell AW, Bak N, Broberg BV, Larsen J, Ishøy PL, Vilsbøll T, Knop FK, Kisely S, Ebdrup BH. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis. Diabetes Obes Metab 2019;21:293-302. [DOI: 10.1111/dom.13522] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 10.8] [Reference Citation Analysis]
25 Mangan A, Docherty NG, Le Roux CW, Al-Najim W. Current and emerging pharmacotherapy for prediabetes: are we moving forward? Expert Opin Pharmacother 2018;19:1663-73. [PMID: 30198813 DOI: 10.1080/14656566.2018.1517155] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
26 Yammine L, Kosten TR, Cinciripini PM, Green CE, Meininger JC, Minnix JA, Newton TF. Exenatide once weekly for smoking cessation: study protocol for a randomized clinical trial. Medicine (Baltimore) 2018;97:e9567. [PMID: 29480848 DOI: 10.1097/MD.0000000000009567] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
27 Kelly AS, Fox CK. Role of Pharmacotherapy in the Treatment of Pediatric Obesity and Its Comorbidities. Contemporary Endocrinology 2018. [DOI: 10.1007/978-3-319-68192-4_35] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-jack S, Defronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, Mcgill JB, Mechanick JI, Rosenblit PD, Umpierrez GE. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary. Endocrine Practice 2018;24:91-121. [DOI: 10.4158/cs-2017-0153] [Cited by in Crossref: 326] [Cited by in F6Publishing: 341] [Article Influence: 81.5] [Reference Citation Analysis]
29 Haw JS, Galaviz KI, Straus AN, Kowalski AJ, Magee MJ, Weber MB, Wei J, Narayan KMV, Ali MK. Long-term Sustainability of Diabetes Prevention Approaches: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med 2017;177:1808-17. [PMID: 29114778 DOI: 10.1001/jamainternmed.2017.6040] [Cited by in Crossref: 167] [Cited by in F6Publishing: 173] [Article Influence: 33.4] [Reference Citation Analysis]
30 Scott RA, Freitag DF, Li L, Chu AY, Surendran P, Young R, Grarup N, Stancáková A, Chen Y, Varga TV, Yaghootkar H, Luan J, Zhao JH, Willems SM, Wessel J, Wang S, Maruthur N, Michailidou K, Pirie A, van der Lee SJ, Gillson C, Al Olama AA, Amouyel P, Arriola L, Arveiler D, Aviles-Olmos I, Balkau B, Barricarte A, Barroso I, Garcia SB, Bis JC, Blankenberg S, Boehnke M, Boeing H, Boerwinkle E, Borecki IB, Bork-Jensen J, Bowden S, Caldas C, Caslake M, Cupples LA, Cruchaga C, Czajkowski J, den Hoed M, Dunn JA, Earl HM, Ehret GB, Ferrannini E, Ferrieres J, Foltynie T, Ford I, Forouhi NG, Gianfagna F, Gonzalez C, Grioni S, Hiller L, Jansson JH, Jørgensen ME, Jukema JW, Kaaks R, Kee F, Kerrison ND, Key TJ, Kontto J, Kote-Jarai Z, Kraja AT, Kuulasmaa K, Kuusisto J, Linneberg A, Liu C, Marenne G, Mohlke KL, Morris AP, Muir K, Müller-Nurasyid M, Munroe PB, Navarro C, Nielsen SF, Nilsson PM, Nordestgaard BG, Packard CJ, Palli D, Panico S, Peloso GM, Perola M, Peters A, Poole CJ, Quirós JR, Rolandsson O, Sacerdote C, Salomaa V, Sánchez MJ, Sattar N, Sharp SJ, Sims R, Slimani N, Smith JA, Thompson DJ, Trompet S, Tumino R, van der A DL, van der Schouw YT, Virtamo J, Walker M, Walter K, Abraham JE, Amundadottir LT, Aponte JL, Butterworth AS, Dupuis J, Easton DF, Eeles RA, Erdmann J, Franks PW, Frayling TM, Hansen T, Howson JM, Jørgensen T, Kooner J, Laakso M, Langenberg C, McCarthy MI, Pankow JS, Pedersen O, Riboli E, Rotter JI, Saleheen D, Samani NJ, Schunkert H, Vollenweider P, O'Rahilly S, Deloukas P, Danesh J, Goodarzi MO, Kathiresan S, Meigs JB, Ehm MG, Wareham NJ, Waterworth DM; CVD50 consortium., GERAD_EC Consortium., Neurology Working Group of the Cohorts for Heart., Aging Research in Genomic Epidemiology (CHARGE)., Alzheimer’s Disease Genetics Consortium., Pancreatic Cancer Cohort Consortium., European Prospective Investigation into Cancer and Nutrition–Cardiovascular Disease (EPIC-CVD)., EPIC-InterAct., CHARGE consortium., CHD Exome+ Consortium., CARDIOGRAM Exome Consortium. A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. Sci Transl Med 2016;8:341ra76. [PMID: 27252175 DOI: 10.1126/scitranslmed.aad3744] [Cited by in Crossref: 80] [Cited by in F6Publishing: 81] [Article Influence: 16.0] [Reference Citation Analysis]
31 Kelly AS, Fox CK. Pharmacotherapy in the Management of Pediatric Obesity. Curr Diab Rep 2017;17:55. [PMID: 28646356 DOI: 10.1007/s11892-017-0886-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
32 Bessesen DH, Van Gaal LF. Progress and challenges in anti-obesity pharmacotherapy. Lancet Diabetes Endocrinol 2018;6:237-48. [PMID: 28919062 DOI: 10.1016/S2213-8587(17)30236-X] [Cited by in Crossref: 129] [Cited by in F6Publishing: 113] [Article Influence: 25.8] [Reference Citation Analysis]
33 Mazzucca AC, Parra MT, Latorraca CO, Spinola-castro AM, Riera R. Glucagon-like peptide (GLP)-1 analogues for normoglycaemic, overweight or obese adults. Cochrane Database of Systematic Reviews 2017. [DOI: 10.1002/14651858.cd012793] [Reference Citation Analysis]
34 Zhang H, Wang C, Ren Y, Wang B, Yang X, Zhao Y, Han C, Zhou J, Zhang L, Qi M, Zhai Y, Pang C, Yin L, Zhao J, Hu D, Zhang M. A risk-score model for predicting risk of type 2 diabetes mellitus in a rural Chinese adult population: A cohort study with a 6-year follow-up. Diabetes Metab Res Rev 2017;33:e2911. [DOI: 10.1002/dmrr.2911] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
35 Styne DM, Arslanian SA, Connor EL, Farooqi IS, Murad MH, Silverstein JH, Yanovski JA. Pediatric Obesity-Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2017;102:709-57. [PMID: 28359099 DOI: 10.1210/jc.2016-2573] [Cited by in Crossref: 463] [Cited by in F6Publishing: 540] [Article Influence: 92.6] [Reference Citation Analysis]
36 Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev 2017;5:CD012204. [PMID: 28489279 DOI: 10.1002/14651858.CD012204.pub2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
37 le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, Ortiz RV, Wilding JPH, Skjøth TV, Manning LS, Pi-Sunyer X; SCALE Obesity Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 2017;389:1399-409. [PMID: 28237263 DOI: 10.1016/S0140-6736(17)30069-7] [Cited by in Crossref: 360] [Cited by in F6Publishing: 364] [Article Influence: 72.0] [Reference Citation Analysis]
38 Farr OM, Mantzoros CS. Treating prediabetes in the obese: are GLP-1 analogues the answer? Lancet 2017;389:1371-2. [PMID: 28237265 DOI: 10.1016/S0140-6736(17)30315-X] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
39 Knop FK, Brønden A, Vilsbøll T. Exenatide: pharmacokinetics, clinical use, and future directions. Expert Opin Pharmacother 2017;18:555-71. [PMID: 28085521 DOI: 10.1080/14656566.2017.1282463] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 8.2] [Reference Citation Analysis]
40 Kirk SF, Shamliyan TA, Middleton M. Glucagon-like peptide-1 agonists for weight loss in people with obesity. Obesity Medicine 2017;5:29-43. [DOI: 10.1016/j.obmed.2017.01.003] [Reference Citation Analysis]
41 Webb D, Abrahamsson N, Sundbom M, Hellström PM. Bariatric surgery – time to replace with GLP-1? Scandinavian Journal of Gastroenterology 2017;52:635-40. [DOI: 10.1080/00365521.2017.1293154] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
42 Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE. Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm - 2017 Executive Summary. Endocr Pract. 2017;23:207-238. [PMID: 28095040 DOI: 10.4158/ep161682.cs] [Cited by in Crossref: 312] [Cited by in F6Publishing: 330] [Article Influence: 62.4] [Reference Citation Analysis]
43 Farr OM, Mantzoros CS. Treatment options to prevent diabetes in subjects with prediabetes: Efficacy, cost effectiveness and future outlook. Metabolism 2017;70:192-5. [PMID: 28095990 DOI: 10.1016/j.metabol.2016.12.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
44 Advances in Pharmacological Treatment of Pediatric Obesity. Childhood Obesity 2016. [DOI: 10.1201/9781315370958-31] [Reference Citation Analysis]
45 Narayanaswami V, Dwoskin LP. Obesity: Current and potential pharmacotherapeutics and targets. Pharmacol Ther 2017;170:116-47. [PMID: 27773782 DOI: 10.1016/j.pharmthera.2016.10.015] [Cited by in Crossref: 101] [Cited by in F6Publishing: 108] [Article Influence: 16.8] [Reference Citation Analysis]
46 Isaacs D, Prasad-reddy L, Srivastava SB. Role of glucagon-like peptide 1 receptor agonists in management of obesity. American Journal of Health-System Pharmacy 2016;73:1493-507. [DOI: 10.2146/ajhp150990] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
47 Burcelin R, Gourdy P. Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity: GLP-1 receptor agonists in overweight and obesity. Obesity Reviews 2017;18:86-98. [DOI: 10.1111/obr.12465] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
48 Su N, Li Y, Xu T, Li L, Kwong JS, Du H, Ren K, Li Q, Li J, Sun X, Li S, Tian H. Exenatide in obese or overweight patients without diabetes: A systematic review and meta-analyses of randomized controlled trials. International Journal of Cardiology 2016;219:293-300. [DOI: 10.1016/j.ijcard.2016.06.028] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
49 Tomlinson B, Hu M, Zhang Y, Chan P, Liu ZM. Investigational glucagon-like peptide-1 agonists for the treatment of obesity. Expert Opin Investig Drugs 2016;25:1167-79. [PMID: 27563838 DOI: 10.1080/13543784.2016.1221925] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
50 Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA. Consensus statement by the american association of clinical endocrinologists and american college of endocrinology on the comprehensive type 2 diabetes management algorithm--2016 executive summary. Endocr Pract. 2016;22:84-113. [PMID: 26731084 DOI: 10.4158/ep151126.cs] [Cited by in Crossref: 310] [Cited by in F6Publishing: 348] [Article Influence: 51.7] [Reference Citation Analysis]
51 Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE; American Association of Clinical Endocrinologists (AACE)., American College of Endocrinology (ACE). CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2015 EXECUTIVE SUMMARY. Endocr Pract 2015;21:1403-14. [PMID: 26642101 DOI: 10.4158/EP151063.CS] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
52 Ionut V, Woolcott OO, Mkrtchyan HJ, Stefanovski D, Kabir M, Iyer MS, Liu H, Castro AV, Wu Q, Broussard JL, Kolka CM, Asare-Bediako I, Bergman RN. Exenatide Treatment Alone Improves β-Cell Function in a Canine Model of Pre-Diabetes. PLoS One 2016;11:e0158703. [PMID: 27398720 DOI: 10.1371/journal.pone.0158703] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
53 Plock N, Bax L, Lee D, DeManno D, Lahu G, Pfister M. Exploratory Literature Meta-Analysis to Characterize the Relationship Between Early and Longer Term Body Weight Loss for Antiobesity Compounds. J Clin Pharmacol 2017;57:52-63. [PMID: 27277818 DOI: 10.1002/jcph.781] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
54 Schwartz SS, Jellinger PS, Herman ME. Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy’s safety profile. Postgraduate Medicine 2016;128:609-19. [DOI: 10.1080/00325481.2016.1191955] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
55 Samson SL, Garber AJ. Prevention of type 2 Diabetes Mellitus: Potential of pharmacological agents. Best Practice & Research Clinical Endocrinology & Metabolism 2016;30:357-71. [DOI: 10.1016/j.beem.2016.06.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
56 López-lópez J, Di Stefano KA, Velásquez E, Camacho PA, López-jaramillo P. ¿Existe un espacio para los análogos de la incretina como terapia para el sobrepeso, la obesidad y la prevención de la enfermedad cardio-metabólica? Revista Colombiana de Cardiología 2016;23:200-9. [DOI: 10.1016/j.rccar.2015.10.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
57 Salehi P, Hsu I, Azen CG, Mittelman SD, Geffner ME, Jeandron D. Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome. Pediatr Obes 2017;12:221-8. [PMID: 27071367 DOI: 10.1111/ijpo.12131] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 6.3] [Reference Citation Analysis]
58 Mayfield K, Siskind D, Winckel K, Russell AW, Kisely S, Smith G, Hollingworth S. Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes. J Psychopharmacol 2016;30:227-36. [PMID: 26801056 DOI: 10.1177/0269881115625496] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
59 Niafar M, Pourafkari L, Porhomayon J, Nader N. A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries. Arch Gynecol Obstet 2016;293:509-15. [DOI: 10.1007/s00404-015-3976-7] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 5.4] [Reference Citation Analysis]
60 Irwin N, Flatt PR. New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders. World J Diabetes 2015; 6(15): 1285-1295 [PMID: 26557956 DOI: 10.4239/wjd.v6.i15.1285] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 46] [Article Influence: 6.6] [Reference Citation Analysis]
61 Acosta A, Camilleri M, Burton D, O'Neill J, Eckert D, Carlson P, Zinsmeister AR. Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study. Physiol Rep 2015;3:e12610. [PMID: 26542264 DOI: 10.14814/phy2.12610] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
62 Dar S, Tahrani AA, Piya MK. The role of GLP-1 receptor agonists as weight loss agents in patients with and without type 2 diabetes: The role of GLP-1 receptor agonists as weight loss agents. Pract Diab 2015;32:297-300b. [DOI: 10.1002/pdi.1978] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
63 ten Kulve JS, Veltman DJ, van Bloemendaal L, Barkhof F, Deacon CF, Holst JJ, Konrad RJ, Sloan JH, Drent ML, Diamant M, IJzerman RG. Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes. Diabetologia 2015;58:2688-98. [PMID: 26385462 DOI: 10.1007/s00125-015-3754-x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 8.7] [Reference Citation Analysis]
64 Fujioka K. Current and emerging medications for overweight or obesity in people with comorbidities. Diabetes Obes Metab. 2015;17:1021-1032. [PMID: 26040215 DOI: 10.1111/dom.12502] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 6.6] [Reference Citation Analysis]
65 Aroda VR, Getaneh A. Guiding diabetes screening and prevention: rationale, recommendations and remaining challenges. Expert Rev Endocrinol Metab 2015;10:381-98. [PMID: 30293496 DOI: 10.1586/17446651.2015.1054280] [Reference Citation Analysis]
66 Candeias EM, Sebastião IC, Cardoso SM, Correia SC, Carvalho CI, Plácido AI, Santos MS, Oliveira CR, Moreira PI, Duarte AI. Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide. World J Diabetes 2015; 6(6): 807-827 [PMID: 26131323 DOI: 10.4239/wjd.v6.i6.807] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 50] [Article Influence: 7.0] [Reference Citation Analysis]
67 Garber AJ. Anti-Obesity Pharmacotherapy and the Potential for Preventing Progression from Prediabetes to Type 2 Diabetes. Endocrine Practice 2015;21:634-44. [DOI: 10.4158/ep14460.ra] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
68 de Mello AH, Prá M, Cardoso LC, de Bona Schraiber R, Rezin GT. Incretin-based therapies for obesity treatment. Metabolism 2015;64:967-81. [PMID: 26072135 DOI: 10.1016/j.metabol.2015.05.012] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
69 Ryan D, Acosta A. GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond. Obesity (Silver Spring). 2015;23:1119-1129. [PMID: 25959380 DOI: 10.1002/oby.21107] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 7.1] [Reference Citation Analysis]
70 Bansal N. Prediabetes diagnosis and treatment: A review. World J Diabetes 2015; 6(2): 296-303 [PMID: 25789110 DOI: 10.4239/wjd.v6.i2.296] [Cited by in CrossRef: 243] [Cited by in F6Publishing: 256] [Article Influence: 34.7] [Reference Citation Analysis]
71 Hollander P, Spellman C. Controversies in Prediabetes: Do We Have a Diagnosis? Postgraduate Medicine 2015;124:109-18. [DOI: 10.3810/pgm.2012.07.2562] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
72 Iglesias P, Civantos S, Vega B, Pavón I, Guijarro G, Monereo S. Clinical Effectiveness of Exenatide in Diabetic Patients Waiting for Bariatric Surgery. OBES SURG 2015;25:575-8. [DOI: 10.1007/s11695-014-1563-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
73 Papaetis GS. Incretin-based therapies in prediabetes: Current evidence and future perspectives. World J Diabetes 2014; 5(6): 817-834 [PMID: 25512784 DOI: 10.4239/wjd.v5.i6.817] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
74 Bethel MA, Xu W, Theodorakis MJ. Pharmacological interventions for preventing or delaying onset of type 2 diabetes mellitus. Diabetes Obes Metab 2015;17:231-44. [PMID: 25312701 DOI: 10.1111/dom.12401] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
75 Iepsen EW, Torekov SS, Holst JJ. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity. Expert Opin Pharmacother 2014;15:2487-500. [PMID: 25260877 DOI: 10.1517/14656566.2014.965678] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
76 Zhang F, Tong Y, Su N, Li Y, Tang L, Huang L, Tong N. Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials-1/:meta. J Diabetes. 2015;7:329-339. [PMID: 25043423 DOI: 10.1111/1753-0407.12198] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
77 Hoelmkjaer KM, Bjornvad CR. Management of obesity in cats. Vet Med (Auckl) 2014;5:97-107. [PMID: 32670850 DOI: 10.2147/VMRR.S40869] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
78 Daniele G, Abdul-Ghani M, DeFronzo RA. What are the pharmacotherapy options for treating prediabetes? Expert Opin Pharmacother 2014;15:2003-18. [PMID: 25139488 DOI: 10.1517/14656566.2014.944160] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
79 Katsurada K, Maejima Y, Nakata M, Kodaira M, Suyama S, Iwasaki Y, Kario K, Yada T. Endogenous GLP-1 acts on paraventricular nucleus to suppress feeding: projection from nucleus tractus solitarius and activation of corticotropin-releasing hormone, nesfatin-1 and oxytocin neurons. Biochem Biophys Res Commun. 2014;451:276-281. [PMID: 25089000 DOI: 10.1016/j.bbrc.2014.07.116] [Cited by in Crossref: 65] [Cited by in F6Publishing: 56] [Article Influence: 8.1] [Reference Citation Analysis]
80 Ottney A. Glucagon-like peptide-1 receptor agonists for weight loss in adult patients without diabetes. Am J Health Syst Pharm. 2013;70:2097-2103. [PMID: 24249759 DOI: 10.2146/ajhp130081] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
81 Li WX, Gou JF, Yan X, Yang L. Metformin for obesity or overweight. Cochrane Database of Systematic Reviews 2014. [DOI: 10.1002/14651858.cd008835.pub2] [Reference Citation Analysis]
82 Goswami G, Shinkazh N, Davis N. Optimal Pharmacologic Treatment Strategies in Obesity and Type 2 Diabetes. J Clin Med 2014;3:595-613. [PMID: 26237392 DOI: 10.3390/jcm3020595] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
83 Ma J, Lin TC, Liu W. Gastrointestinal hormones and polycystic ovary syndrome. Endocrine 2014;47:668-78. [PMID: 24791734 DOI: 10.1007/s12020-014-0275-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
84 Ahmadieh H, Azar ST. The role of incretin-based therapies in prediabetes: a review. Prim Care Diabetes. 2014;8:286-294. [PMID: 24666932 DOI: 10.1016/j.pcd.2014.02.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
85 Portero McLellan KC, Wyne K, Villagomez ET, Hsueh WA. Therapeutic interventions to reduce the risk of progression from prediabetes to type 2 diabetes mellitus. Ther Clin Risk Manag 2014;10:173-88. [PMID: 24672242 DOI: 10.2147/TCRM.S39564] [Cited by in Crossref: 9] [Cited by in F6Publishing: 36] [Article Influence: 1.1] [Reference Citation Analysis]
86 van Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol. 2014;221:T1-16. [PMID: 24323912 DOI: 10.1530/joe-13-0414] [Cited by in Crossref: 142] [Cited by in F6Publishing: 148] [Article Influence: 17.8] [Reference Citation Analysis]
87 Gallwitz B. Extra-pancreatic effects of incretin-based therapies. Endocrine 2014;47:360-71. [PMID: 24604239 DOI: 10.1007/s12020-014-0223-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
88 Chatzigeorgiou A, Kandaraki E, Papavassiliou AG, Koutsilieris M. Peripheral targets in obesity treatment: a comprehensive update. Obes Rev. 2014;15:487-503. [PMID: 24612276 DOI: 10.1111/obr.12163] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
89 Jensterle Sever M, Kocjan T, Pfeifer M, Kravos NA, Janez A. Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol. 2014;170:451-459. [PMID: 24362411 DOI: 10.1530/eje-13-0797] [Cited by in Crossref: 87] [Cited by in F6Publishing: 92] [Article Influence: 10.9] [Reference Citation Analysis]
90 Kishimoto M, Noda M. Effects of exenatide in a morbidly obese patient with type 2 diabetes. Diabetes Ther 2014;5:323-32. [PMID: 24442463 DOI: 10.1007/s13300-014-0050-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
91 Seufert J, Gallwitz B. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. Diabetes Obes Metab. 2014;16:673-688. [PMID: 24373150 DOI: 10.1111/dom.12251] [Cited by in Crossref: 71] [Cited by in F6Publishing: 78] [Article Influence: 8.9] [Reference Citation Analysis]
92 Christensen M, Knop FK, Vilsbøll T. The GetGoal clinical trial program of lixisenatide, a once-daily GLP-1 receptor agonist. Expert Review of Endocrinology & Metabolism 2014;6:513-25. [DOI: 10.1586/eem.11.30] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
93 Kelly AS. The role of glucagon-like peptide-1 receptor agonists for the treatment of adolescent obesity. Expert Rev Endocrinol Metab 2013;8:315-7. [PMID: 30736144 DOI: 10.1586/17446651.2013.811913] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
94 Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014;311:74-86. [PMID: 24231879 DOI: 10.1001/jama.2013.281361] [Cited by in Crossref: 558] [Cited by in F6Publishing: 583] [Article Influence: 69.8] [Reference Citation Analysis]
95 Pasarica M, Smith SR. Drugs for Weight Loss and Maintenance: Present and Future. Treatment of the Obese Patient 2014. [DOI: 10.1007/978-1-4939-2311-3_16] [Reference Citation Analysis]
96 Fujishima Y, Maeda N. Effect of Glucagon-Like Peptide 1 Receptor Agonists on Visceral Fat Adiposity, Appetite, and Food Preference. Nutrition in the Prevention and Treatment of Abdominal Obesity 2014. [DOI: 10.1016/b978-0-12-407869-7.00015-5] [Reference Citation Analysis]
97 Pasarica M, Smith SR. Drugs for Weight Loss and Maintenance: Present and Future. Treatment of the Obese Patient 2014. [DOI: 10.1007/978-1-4939-1203-2_16] [Reference Citation Analysis]
98 Chen H, Simar D, Pegg K, Saad S, Palmer C, Morris MJ. Exendin-4 is effective against metabolic disorders induced by intrauterine and postnatal overnutrition in rodents. Diabetologia. 2014;57:614-622. [PMID: 24337156 DOI: 10.1007/s00125-013-3132-5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
99 Kim SH, Liu A, Ariel D, Abbasi F, Lamendola C, Grove K, Tomasso V, Reaven G. Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study. Diabetologia. 2014;57:455-462. [PMID: 24326527 DOI: 10.1007/s00125-013-3134-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
100 Anderson ZL, Scopelliti EM, Trompeter JM, Havrda DE. Management of Prediabetes: A Comparison of the Treatment Approaches Utilized by a Family Practice Clinic and an Internal Medicine/Endocrinology Practice. Journal of Pharmacy Practice 2015;28:86-92. [DOI: 10.1177/0897190013514089] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
101 Ho CH, Yu HJ, Wang CY, Jaw FS, Hsieh JT, Liao WC, Pu YS, Liu SP. Prediabetes is associated with an increased risk of testosterone deficiency, independent of obesity and metabolic syndrome. PLoS One 2013;8:e74173. [PMID: 24069277 DOI: 10.1371/journal.pone.0074173] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
102 Page KA, Reisman T. Interventions to preserve beta-cell function in the management and prevention of type 2 diabetes. Curr Diab Rep 2013;13:252-60. [PMID: 23371283 DOI: 10.1007/s11892-013-0363-2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
103 Simon M, Roden M, Müssig K. Inkretine. Diabetologe 2013;9:463-466. [DOI: 10.1007/s11428-013-1058-7] [Reference Citation Analysis]
104 Kim SH, Abbasi F, Lamendola C, Liu A, Ariel D, Schaaf P, Grove K, Tomasso V, Ochoa H, Liu YV. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care. 2013;36:3276-3282. [PMID: 23835684 DOI: 10.2337/dc13-0354] [Cited by in Crossref: 59] [Cited by in F6Publishing: 65] [Article Influence: 6.6] [Reference Citation Analysis]
105 Bloomgarden ZT, Blonde L, Garber AJ, Wysham CH. Current issues in GLP-1 receptor agonist therapy for type 2 diabetes. Endocr Pract 2012;18 Suppl 3:6-26; quiz 27-8. [PMID: 23315305 DOI: 10.4158/EP12300.RA] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
106 Kelly AS, Rudser KD, Nathan BM, Fox CK, Metzig AM, Coombes BJ, Fitch AK, Bomberg EM, Abuzzahab MJ. The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial. JAMA Pediatr. 2013;167:355-360. [PMID: 23380890 DOI: 10.1001/jamapediatrics.2013.1045] [Cited by in Crossref: 111] [Cited by in F6Publishing: 115] [Article Influence: 12.3] [Reference Citation Analysis]
107 Hasani-Ranjbar S, Jouyandeh Z, Abdollahi M. A systematic review of anti-obesity medicinal plants - an update. J Diabetes Metab Disord 2013;12:28. [PMID: 23777875 DOI: 10.1186/2251-6581-12-28] [Cited by in Crossref: 115] [Cited by in F6Publishing: 121] [Article Influence: 12.8] [Reference Citation Analysis]
108 Ellenbroek JH, Töns HAM, Westerouen van Meeteren MJA, de Graaf N, Hanegraaf MA, Rabelink TJ, Carlotti F, de Koning EJP. Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice. Diabetologia 2013;56:1980-6. [DOI: 10.1007/s00125-013-2957-2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
109 Madsbad S. The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications. Diabetes Obes Metab 2014;16:9-21. [DOI: 10.1111/dom.12119] [Cited by in Crossref: 88] [Cited by in F6Publishing: 93] [Article Influence: 9.8] [Reference Citation Analysis]
110 Ling H, Lenz TL, Burns TL, Hilleman DE. Reducing the risk of obesity: defining the role of weight loss drugs. Pharmacotherapy 2013;33:1308-21. [PMID: 23712541 DOI: 10.1002/phar.1277] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
111 Masuda K, Aoki K, Kamiko K, Takihata M, Ito Y, Nagakura M, Kawasaki S, Akema N, Hasegawa M, Nakajima S, Shinoda K, Toumura S, Tsunoda S, Enomoto H, Shimotomai H, Terauchi Y. Glycemic control after addition of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes showing inadequate response to thrice-a-day treatment with α-glucosidase inhibitors. Expert Opinion on Pharmacotherapy 2013;14:1111-8. [DOI: 10.1517/14656566.2013.790365] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
112 Zoicas F, Droste M, Mayr B, Buchfelder M, Schöfl C. GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases. Eur J Endocrinol 2013;168:699-706. [PMID: 23392214 DOI: 10.1530/EJE-12-0997] [Cited by in Crossref: 70] [Cited by in F6Publishing: 72] [Article Influence: 7.8] [Reference Citation Analysis]
113 Powers PS, Cloak NL. Psychopharmacologic treatment of obesity and eating disorders in children and adolescents. Child Adolesc Psychiatr Clin N Am 2012;21:831-59. [PMID: 23040904 DOI: 10.1016/j.chc.2012.07.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
114 Holst JJ, Deacon CF. Is there a place for incretin therapies in obesity and prediabetes? Trends Endocrinol Metab 2013;24:145-52. [PMID: 23415157 DOI: 10.1016/j.tem.2013.01.004] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
115 Holst JJ. Incretin hormones and the satiation signal. Int J Obes (Lond). 2013;37:1161-1168. [PMID: 23295502 DOI: 10.1038/ijo.2012.208] [Cited by in Crossref: 108] [Cited by in F6Publishing: 115] [Article Influence: 12.0] [Reference Citation Analysis]
116 Pedersen SD. Impact of Newer Medications for Type 2 Diabetes on Body Weight. Curr Obes Rep 2013;2:134-41. [DOI: 10.1007/s13679-012-0045-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
117 Moreno JL, Willett KC, Desilets AR. Exenatide as a Novel Weight Loss Modality in Patients Without Diabetes. Ann Pharmacother 2012;46:1700-6. [DOI: 10.1345/aph.1r372] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
118 Montanya E. A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2012;13:1451-1467. [PMID: 22725703 DOI: 10.1517/14656566.2012.692777] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
119 Baynes KC. The evolving world of GLP-1 agonist therapies for type 2 diabetes. Ther Adv Endocrinol Metab 2010;1:61-7. [PMID: 23148151 DOI: 10.1177/2042018810375414] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
120 Shin J, Chang JS, Kim HS, Ko SH, Cha BY, Son HY, Yoon KH, Cho JH. Effects of a 6-Month Exenatide Therapy on HbA1c and Weight in Korean Patients with Type 2 Diabetes: A Retrospective Cohort Study. Diabetes Metab J 2012;36:364-70. [PMID: 23130321 DOI: 10.4093/dmj.2012.36.5.364] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
121 Choudhary N, Kalra S, Unnikrishnan AG, Ajish TP. Preventive pharmacotherapy in type 2 diabetes mellitus. Indian J Endocrinol Metab 2012;16:33-43. [PMID: 22276251 DOI: 10.4103/2230-8210.91183] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
122 Armato J, DeFronzo RA, Abdul-Ghani M, Ruby R. Successful treatment of prediabetes in clinical practice: targeting insulin resistance and β-cell dysfunction. Endocr Pract. 2012;18:342-350. [PMID: 22068250 DOI: 10.4158/ep11194.or] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
123 Hayes MR, Kanoski SE, Alhadeff AL, Grill HJ. Comparative Effects of the Long-Acting GLP-1 Receptor Ligands, Liraglutide and Exendin-4, on Food Intake and Body Weight Suppression in Rats. Obesity 2011;19:1342-9. [DOI: 10.1038/oby.2011.50] [Cited by in Crossref: 79] [Cited by in F6Publishing: 82] [Article Influence: 7.9] [Reference Citation Analysis]
124 Niswender K, Pi-Sunyer X, Buse J, Jensen KH, Toft AD, Russell-Jones D, Zinman B. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes Obes Metab 2013;15:42-54. [PMID: 22862847 DOI: 10.1111/j.1463-1326.2012.01673.x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 77] [Article Influence: 6.9] [Reference Citation Analysis]
125 Kautzky-willer A, Lemmens-gruber R. Obesity and Diabetes. In: Regitz-zagrosek V, editor. Sex and Gender Differences in Pharmacology. Berlin: Springer Berlin Heidelberg; 2012. pp. 307-40. [DOI: 10.1007/978-3-642-30726-3_15] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
126 Cho YM, Merchant CE, Kieffer TJ. Targeting the glucagon receptor family for diabetes and obesity therapy. Pharmacology & Therapeutics 2012;135:247-78. [DOI: 10.1016/j.pharmthera.2012.05.009] [Cited by in Crossref: 111] [Cited by in F6Publishing: 93] [Article Influence: 11.1] [Reference Citation Analysis]
127 Riediger T. The receptive function of hypothalamic and brainstem centres to hormonal and nutrient signals affecting energy balance. Proc Nutr Soc 2012;71:463-77. [PMID: 22931748 DOI: 10.1017/S0029665112000778] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
128 Sherafat-Kazemzadeh R, Yanovski SZ, Yanovski JA. Pharmacotherapy for childhood obesity: present and future prospects. Int J Obes (Lond) 2013;37:1-15. [PMID: 22929210 DOI: 10.1038/ijo.2012.144] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 4.2] [Reference Citation Analysis]
129 Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379:2279-2290. [PMID: 22683128 DOI: 10.1016/s0140-6736(12)60283-9] [Cited by in Crossref: 1388] [Cited by in F6Publishing: 1478] [Article Influence: 138.8] [Reference Citation Analysis]
130 Kelly AS, Bergenstal RM, Gonzalez-Campoy JM, Katz H, Bank AJ. Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. Cardiovasc Diabetol. 2012;11:64. [PMID: 22681705 DOI: 10.1186/1475-2840-11-64] [Cited by in Crossref: 67] [Cited by in F6Publishing: 72] [Article Influence: 6.7] [Reference Citation Analysis]
131 Aoki K, Kamiyama H, Yoshimura K, Shibuya M, Masuda K, Terauchi Y. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin. Acta Diabetol 2012;49:225-30. [PMID: 21898126 DOI: 10.1007/s00592-011-0322-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
132 Monami M, Dicembrini I, Marchionni N, Rotella CM, Mannucci E. Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis. Exp Diabetes Res. 2012;2012:672658. [PMID: 22675341 DOI: 10.1155/2012/672658] [Cited by in Crossref: 42] [Cited by in F6Publishing: 60] [Article Influence: 4.2] [Reference Citation Analysis]
133 Lind M. Incretin therapy and its effect on body weight in patients with diabetes. Prim Care Diabetes. 2012;6:187-191. [PMID: 22613745 DOI: 10.1016/j.pcd.2012.04.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
134 Bourey R, Lambert C. Drug Treatment of Obesity. Obesity 2012. [DOI: 10.1201/b12085-11] [Reference Citation Analysis]
135 Kabra DG, Kabra UD, Tschöp MH, Hofmann S. Pharmacological Treatment of Obesity. In: Shiromani P, Horvath T, Redline S, Van Cauter E, editors. Sleep Loss and Obesity. New York: Springer; 2012. pp. 203-25. [DOI: 10.1007/978-1-4614-3492-4_14] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
136 Vickers SP, Clifton PG. Animal models to explore the effects of CNS drugs on food intake and energy expenditure. Neuropharmacology 2012;63:124-31. [PMID: 22710443 DOI: 10.1016/j.neuropharm.2012.04.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
137 Simonyi G, Pados G, Medvegy M, Bedros JR. The pharmacological treatment of obesity: Past, present and future. Orvosi Hetilap 2012;153:363-73. [DOI: 10.1556/oh.2012.29317] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
138 Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012;344:d7771. [PMID: 22236411 DOI: 10.1136/bmj.d7771] [Cited by in Crossref: 570] [Cited by in F6Publishing: 601] [Article Influence: 57.0] [Reference Citation Analysis]
139 Cernea S. The role of incretin therapy at different stages of diabetes. Rev Diabet Stud. 2011;8:323-338. [PMID: 22262070 DOI: 10.1900/rds.2011.8.323] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
140 Kelly AS, Metzig AM, Rudser KD, Fitch AK, Fox CK, Nathan BM, Deering MM, Schwartz BL, Abuzzahab MJ, Gandrud LM, Moran A, Billington CJ, Schwarzenberg SJ. Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study. Obesity (Silver Spring) 2012;20:364-70. [PMID: 22076596 DOI: 10.1038/oby.2011.337] [Cited by in Crossref: 84] [Cited by in F6Publishing: 87] [Article Influence: 7.6] [Reference Citation Analysis]
141 Moscatiello S, Di Luzio R, Sasdelli AS, Marchesini G. Managing the combination of nonalcoholic fatty liver disease and metabolic syndrome. Expert Opin Pharmacother. 2011;12:2657-2672. [PMID: 22043839 DOI: 10.1517/14656566.2011.629188] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
142 Dushay J, Gao C, Gopalakrishnan GS, Crawley M, Mitten EK, Wilker E, Mullington J, Maratos-Flier E. Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes. Diabetes Care. 2012;35:4-11. [PMID: 22040840 DOI: 10.2337/dc11-0931] [Cited by in Crossref: 85] [Cited by in F6Publishing: 92] [Article Influence: 7.7] [Reference Citation Analysis]
143 Folli F, Guardado Mendoza R. Potential use of exenatide for the treatment of obesity. Expert Opin Investig Drugs 2011;20:1717-22. [PMID: 22017240 DOI: 10.1517/13543784.2011.630660] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
144 Garber AJ. Focus on Incretin-Based Therapies for Patients with Type 2 Diabetes and Cardiovascular Disease. Endocrine Practice 2011;17:13-9. [DOI: 10.1016/s1530-891x(20)43147-7] [Reference Citation Analysis]
145 Vergès B, Bonnard C, Renard E. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system. Diabetes Metab 2011;37:477-88. [PMID: 21871831 DOI: 10.1016/j.diabet.2011.07.001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
146 Sullivan SD, Ratner RE. Should the metabolic syndrome patient with prediabetes be offered pharmacotherapy? Curr Diab Rep 2011;11:91-8. [PMID: 21207204 DOI: 10.1007/s11892-010-0170-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
147 Tripathy D, Defronzo RA. Can we prevent diabetes with a single pill? Diabetes Management 2011;1:355-358. [DOI: 10.2217/dmt.11.35] [Reference Citation Analysis]
148 Cernea S, Raz I. Therapy in the early stage: incretins. Diabetes Care. 2011;34 Suppl 2:S264-S271. [PMID: 21525466 DOI: 10.2337/dc11-s223] [Cited by in Crossref: 73] [Cited by in F6Publishing: 81] [Article Influence: 6.6] [Reference Citation Analysis]
149 Torekov SS, Madsbad S, Holst JJ. Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential: Obesity - an indication for GLP-1 treatment? Obesity Reviews 2011;12:593-601. [DOI: 10.1111/j.1467-789x.2011.00860.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 3.8] [Reference Citation Analysis]
150 Christensen M, Knop FK, Vilsbøll T, Holst JJ. Lixisenatide for type 2 diabetes mellitus. Expert Opin Investig Drugs. 2011;20:549-557. [PMID: 21391833 DOI: 10.1517/13543784.2011.562191] [Cited by in Crossref: 57] [Cited by in F6Publishing: 63] [Article Influence: 5.2] [Reference Citation Analysis]
151 Glandt M, Raz I. Present and future: pharmacologic treatment of obesity. J Obes 2011;2011:636181. [PMID: 21331293 DOI: 10.1155/2011/636181] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
152 Kruger DF, Bode B, Spollett GR. Understanding GLP-1 analogs and enhancing patients success. Diabetes Educ 2010;36 Suppl 3:44S-72S; quiz 73S-74S. [PMID: 20736387 DOI: 10.1177/0145721710374370] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
153 de Kloet AD, Woods SC. Molecular neuroendocrine targets for obesity therapy. Curr Opin Endocrinol Diabetes Obes 2010;17:441-5. [PMID: 20585249 DOI: 10.1097/MED.0b013e32833c3013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
154 Simpson KA, Bloom SR. Appetite and Hedonism: Gut Hormones and the Brain. Endocrinology and Metabolism Clinics of North America 2010;39:729-43. [DOI: 10.1016/j.ecl.2010.08.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
155 Li WX, Gou JF, Yan X, Yang L, Yan X. Metformin for obesity or overweight. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd008835] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
156 . Current literature in diabetes. Diabetes Metab Res Rev 2010;26:i-xi. [DOI: 10.1002/dmrr.1029] [Reference Citation Analysis]
157 Cheng V, Kashyap SR. Weight considerations in pharmacotherapy for type 2 diabetes. J Obes 2011;2011:984245. [PMID: 20885921 DOI: 10.1155/2011/984245] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]